Impressive presentation from the team. They sound excited.
With 20% durable CR’s in head and neck we should see very rapid recruitment into the new 2b trial. And, recruitment into expanded NSCLC completed ahead of schedule even with the pandemic. This is getting juicy.
It is interesting that they don’t know exactly why the low monocyte group had such amazing results and it is under investigation. It may be that lower monocytes reflect a compromised immune system(likely considering heavy pre treatment) which Efti is curing.
Confirmation of trial design and FDA/EMA go ahead will be another catalyst that will hopefully arrive just after Relatlimab approval….you know what I’m say’n
Ann: Immutep Global Webcast Slides to Discuss Clinical Results, page-14
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $938.4K | 2.678M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 163013 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 476182 | 36 |
View Market Depth
| Last trade - 15.07pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |